SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, November 4, 2025 — Leads & Copy — ORIC Pharmaceuticals Inc. (Nasdaq: ORIC) will participate in investor conferences in November.
Management will participate in a fireside chat at Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025, at 1:30 p.m. ET, and in one-on-one meetings at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025. Another fireside chat will occur at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025, at 2:30 p.m. GMT.
Webcasts will be available on the company’s website; replays will be available for 90 days following the event.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California.
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
Source: ORIC Pharmaceuticals, Inc.
